The U.S. Food and Drug Administration has approved Datroway (datopotamab deruxtecan-dlnk) for adult patients with ...

The European Medicines Agency has recommended three new medicines to treat breast and cervical cancer and ...

Q3 2024 Management View Revenue for Q3 FY2024 increased 16.6% year-on-year to ¥1,367.6 billion, driven by growth in oncology ...

Daiichi Sankyo appoints Hiroyuki Okuzawa as chief executive officer: Tokyo Saturday, February 1, 2025, 12:30 Hrs [IST] ...

On Friday, the U.S. Food and Drug Administration (FDA) approved AstraZeneca Plc’s (NASDAQ:AZN) Datroway (datopotamab ...

The FDA's nod is based on late-stage data, which show AZN's Datroway cuts the risk of disease progression/death by 37% vs ...

The clearance of Datroway comes months after the companies narrowed approval plans in lung cancer and opens up a market ...

The FDA has approved AstraZeneca and Daiichi Sankyo’s Datroway (datopotamab deruxtecan-dlnk) to treat unresectable or ...

Following a world-first approval in Japan, AstraZeneca and Daiichi Sankyo’s second antibody-drug conjugate has crossed the ...

Approval is based on results from the TROPION-Breast01 Phase III trial, in which Datroway demonstrated a significant ...

DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.

The FDA approved datopotamab deruxtecan-dlnk for treatment of certain patients with advanced breast cancer.The indication ...